Delaying Hepatitis B Birth Dose Increases Risk of Chronic Infection, Long-Term Liver Disease, Study Finds

The recent shift in federal guidelines on the hepatitis B (HepB) vaccine has sparked significant debate among pediatricians and pharmacists. Although the Advisory Committee on Immunization Practices (ACIP) recently changed the universal birth dose recommendation to a shared clinical decision-making (SCDM) model for infants of positive HepB surface antigen (HBsAg)–negative mothers, data from a new study published in JAMA Pediatrics suggest that delaying this first dose could have significant clinical and economic consequences.¹

Impact of Delayed Vaccination

The study, led by Eric W. Hall, PhD, MPH, used a Markov model to project outcomes of delaying the HepB vaccine from birth to 2 months, 7 months, 4 years, or 12 years. The results demonstrated that even a modest delay to 2 months of age—the current alternative under SCDM guidelines—was projected to result in an additional 90 acute infections and 76 chronic infections per birth cohort.¹

As the delay increased, the public health burden scaled accordingly. A 12-year delay was estimated to cause over 190 additional acute infections and 1600 chronic cases, ultimately leading to hundreds of preventable deaths from cirrhosis and hepatocellular carcinoma (HCC).

Beyond the clinical toll, the study data highlighted that the universal birth dose remains the most cost-effective strategy. The high costs associated with managing chronic liver disease—including annual HCC care costs of approximately $59,368 and liver transplant costs exceeding $203,000—far outweigh the $17.87 cost of a single vaccine dose.¹

Shifting Policy and Clinical Confusion

For decades, the CDC and major health organizations, such as the American Academy of Pediatrics (AAP), have advocated for a “safety net” approach, recommending that the first HepB dose be administered within 24 hours of birth for all medically stable infants. This was designed to prevent perinatal transmission in cases where maternal screening was missed or failed.^2,3

However, as of early 2026, the Department of Health and Human Services and the CDC modified the childhood immunization schedule, moving HepB vaccination for low-risk infants into the SCDM category. Under this new framework, the birth dose is only routinely recommended for infants born to HBsAg-positive mothers or those with unknown status. Experts worry that this flexibility may lead to inconsistency in coverage and further erode public trust in the vaccine’s necessity.^2,4

The Pharmacist’s Role in Shared Decision-Making

Regarding SCDM, the pharmacist’s role as an advocate for evidence-based care is more critical than ever. When counseling parents, it is vital to emphasize that the risk of chronicity is age dependent; approximately 90% of infants infected at birth develop chronic infections, compared with a fraction of those infected in adulthood. Pharmacists should also highlight that the birth dose serves as a highly effective safeguard, providing 75% to 95% protection even if a mother’s HBsAg-negative status was documented incorrectly or if postexposure prophylaxis is missed.³

Ultimately, the conversation should focus on the lifelong protection provided by the 3-dose series. Starting the series at birth ensures the highest probability of completion and provides enduring immunity against HepB, with consequent prevention of HepD infection. By integrating the JAMA Pediatrics data into clinical consultations, pharmacists can provide a compelling narrative that the birth dose is not just a routine procedure but a foundational step in preventing lifelong liver disease.⁴

Evaluating Study Limitations

While the findings provide a compelling argument for the birth dose, the study authors noted several limitations inherent in their modeling. The study used a 1-month time step, which did not allow for a detailed analysis of differences between doses given at 12 hours, 24 hours, or at hospital discharge. Additionally, the model tracked health outcomes only through age 18 years to isolate the impact on the childhood schedule, and it focused on a single birth cohort rather than the total population.¹

The researchers noted that their findings are likely a conservative estimate of the true burden. The model did not account for onward transmission to others, infections occurring after age 18, or the rising risk of community transmission as population prevalence increases. Furthermore, although the study excluded infrequent costs associated with vaccine adverse effects, such as evaluations for unexplained fever, the authors maintained that these factors would not meaningfully shift the overall cost-effectiveness of the birth dose.¹

REFERENCES

1. Hall EW, Gounder P, Bradley H, Nelson NP. Economic impact of delaying the infant hepatitis B vaccination schedule. JAMA Pediatr. 2026;180(4):e261221. doi:10.1001/jamapediatrics.2026.1221

2. Weng MK, Doshani M, Khan MA, et al. Universal hepatitis B vaccination in adults aged 19-59 years: updated recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(13):477-483. doi:10.15585/mmwr.mm7113a1

3. Committee on Infectious Diseases; Committee on Fetus and Newborn. Elimination of perinatal hepatitis B: providing the first vaccine dose within 24 hours of birth. Pediatrics. 2017;140(3):e20171870. doi:10.1542/peds.2017-1870

4. Vaccine schedules. Hepatitis B Foundation. Updated January 2026. Accessed April 30, 2026. https://www.hepb.org/prevention-and-diagnosis/vaccination/guidelines-2/